Sign in Subscribe
Class action lawsuits

Novo Nordisk A/S Faces Securities Class Action Lawsuit

Strategic Insights

— 1 min read

Novo Nordisk A/S, a leading healthcare company, is embroiled in a securities class action lawsuit filed on behalf of investors who purchased or acquired the company's securities between May 7, 2025, and July 28, 2025. The lawsuit alleges that the company's defendants made misrepresentations concerning Novo's growth potential stemming from its diabetes/obesity drug, GLP-1. Investors who purchased shares during this period and lost money in their investment are being encouraged to visit the company's website or contact Investor Relations Manager Peter Allocco to discuss their legal rights and options.

Key Takeaways:

  • A shareholder has filed a securities class action lawsuit against Novo Nordisk A/S on behalf of investors who purchased or acquired the company's securities between May 7, 2025, and July 28, 2025.
  • The lawsuit alleges that the company's defendants made misrepresentations concerning Novo's growth potential stemming from its diabetes/obesity drug, GLP-1.
  • Investors who purchased shares during this period and lost money in their investment can visit the company's website or contact Investor Relations Manager Peter Allocco to discuss their legal rights and options.
  • The lead plaintiff must file papers by September 30, 2025, to direct the litigation.
  • Shareholders pay no fees or expenses as the representation is on a contingency fee basis.
  • Bernstein Liebhard LLP, the law firm responsible for the advertisement, has recovered over $3.5 billion for its clients since 1993.
  • The firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years.

Statistics:

  • The lawsuit alleges that Novo Nordisk A/S made misrepresentations concerning its growth potential.
  • More than $3.5 billion has been recovered by Bernstein Liebhard LLP for its clients since 1993.
  • Bernstein Liebhard LLP has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years.
  • The lead plaintiff must file papers by September 30, 2025, to direct the litigation.

Sources:

  • GlobeNewswire, "Novo Nordisk A/S investor alert: Class action," 2025.
  • COMTEX, COMTEX_468298603/2010/2025-08-25T08:42:20.

Read more